Track market-moving stories before they get noisy

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately 1,402,888 shares changed hands during trading, a decline of 53% from the average daily volume of 2,991,611 shares. The stock had previously closed at $1.82.

Wall Street Analysts Forecast Growth LXRX has been the topic of several research analyst reports. Cantor Fitzgerald started coverage on Lexicon Pharmaceuticals in a research note on Monday, September 28th. They issued an “overweight” rating and a $8.00 price objective on the stock. Weiss Ratings raised Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Zacks Research downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.70.

View Our Latest Research Report on LXRX

The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $2.06. The company has a market cap of $778.68 million, a price-to-earnings ratio of -11.67 and a beta of 1.07. The company has a quick ratio of 13.29, a current ratio of 13.37 and a debt-to-equity ratio of 0.29. Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 37.53% and a negative net margin of 147.38%.The business had revenue of $0.69 million for the quarter, compared to the consensus estimate of $3.99 million. As a group, sell-side analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.17 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals Several large investors have recently modified their holdings of the stock. Siren L.L.C. lifted its position in shares of Lexicon Pharmaceuticals by 13.8% during the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock worth $69,113,000 after buying an additional 5,384,615 shares during the last quarter. Renaissance Technologies LLC grew its position in Lexicon Pharmaceuticals by 508.0% in the first quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock valued at $2,497,000 after acquiring an additional 1,337,246 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Lexicon Pharmaceuticals in the second quarter worth about $1,365,000. ADAR1 Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter valued at approximately $1,170,000. Finally, Ishara Investments LP acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $1,012,000. 74.70% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals (Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for diseases with significant unmet medical needs. The company uses its expertise in human genetics and gene biology to identify novel drug targets and develop small-molecule therapies.

Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral treatment for carcinoid syndrome diarrhea in adults whose symptoms are inadequately controlled by short-acting somatostatin analog therapy.

Featured Articles Five stocks we like better than Lexicon Pharmaceuticals Rivian Escapes the EV Graveyard—But Can It Stay Alive? Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

An analyst's rather bullish initiation of coverage shone a light on Lexicon Pharmaceuticals (LXRX +5.85%) stock on Monday. Investors clearly took notice of this, as they piled into the company's stock to send it to a gain of nearly 6% on the day.

A heartening evaluation Before market open, Cantor Fitzgerald prognosticator Steve Seedhouse flagged Lexicon as an overweight (buy, in other words) at a price target of $8 per share. That's more than four times the stock's current level of $1.90.

Image source: Getty Images.

According to reports, in his inaugural Lexicon analysis, Seedhouse waxed bullish about the company's progress toward earning a new indication for sotagliflozin.

The drug, which has Food and Drug Administration (FDA) approval to treat heart failure and related risks under the brand name Inpefa, is currently being developed for other indications, including hypertrophic cardiomyopathy (HCM; thickening of the heart muscle). Lexicon is currently in late-stage development for this effort.

Premium Feature

Moneyball Superscore

52/100

Today's Change

(

5.85

%) $

0.11

Current Price

$

1.90

Positive indications Seedhouse wrote in his Lexicon take that sotagliflozin works via a different mechanism than other drugs treating HCM. As such, if approved, it will complement instead of compete with them. Heart afflictions are common ailments in this country and around the world, so the potential for the drug is considerable if it wins regulatory green lights for this indication.

That said, no drug is guaranteed approval, no matter how it might have performed in the past. Lexicon is an attractive stock, to be sure, but like any small pharmaceutical and biotech company, its equity carries a higher-than-average degree of risk.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

B of A Securities analyst Vivek Arya initiated coverage on IONQ Inc (NYSE:IONQ) with a Buy rating and announced a price target of $60. IonQ closed at $45.48 on Friday. See how other analysts view this stock. Cantor Fitzgerald analyst Steve Seedhouse initiated coverage on Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) with an Overweight rating and announced a price target of $8. Lexicon Pharmaceuticals shares closed at $1.80 on Friday. See how other analysts view this stock. Evercore ISI Group analyst Alexander Virgo initiated coverage on Fortive Corp (NYSE:FTV) with an In-Line rating and announced a price target of $60. Fortive closed at $56.09 on Friday. See how other analysts view this stock. Seaport Global analyst Jeff Cantwell initiated coverage on Jack Henry & Associates Inc (NASDAQ:JKHY) with a Buy rating and announced a price target of $193. Jack Henry & Associates shares closed at $147.79 on Friday. See how other analysts view this stock. Argus Research analyst John Eade initiated coverage on 10X Genomics Inc (NASDAQ:TXG) with a Buy rating and announced a price target of $110. 10x Genomics closed at $85.71 on Friday. See how other analysts view this stock. Considering buying LXRX stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.

Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executive Officer Dr. Mike Exton said the company is continuing its transition toward a cardiometabolic focus, with sotagliflozin programs in hypertrophic cardiomyopathy, or HCM, and type 1 diabetes among its principal near-term priorities.

Get LXRX alerts:

SONATA-HCM Enrollment Exceeds Target Exton said SONATA-HCM was designed to enroll 500 patients across obstructive and non-obstructive forms of HCM, but the trial ultimately “substantially over-enrolled” that target. Enrollment was completed at the end of July, and the 26-week study uses the Kansas City Cardiomyopathy Questionnaire, or KCCQ, as an endpoint.

The company expects to present baseline demographic information from the trial at an HCM-focused medical meeting after the data are cleaned, Exton said.

Lexicon executives emphasized their view that obstructive and non-obstructive HCM represent a continuum rather than wholly separate diseases. Exton said diastolic dysfunction and left ventricular hypertrophy are central features across the condition, while the distinction between obstructive and non-obstructive disease primarily reflects the location of heart-muscle thickening.

Chief Medical Officer Dr. Craig Granowitz said HCM has historically been defined in part by available treatments, including surgery and therapies that reduce cardiac contractility. He said sotagliflozin is intended to act through multiple mechanisms, including SGLT2-related cardiorenal and decongestion effects as well as potential direct effects on myocardial energetics through SGLT1.

According to Granowitz, SONATA-HCM has broad inclusion criteria, including patients with ejection fractions as low as 50%. The study also permits certain patients using cardiac myosin inhibitors, or CMIs, subject to entry criteria. He contrasted that approach with CMI use in patients with more hyperdynamic heart function.

Commercial Planning and HCM Positioning Exton said Lexicon has begun pre-launch planning for a potential HCM commercialization effort. The company promoted Rachel Martens, previously responsible for partnership and strategy activities, to chief commercial officer. Lexicon also hired a head of marketing, a head of access and five medical science liaisons, he said.

The company is conducting market research on the potential positioning of sotagliflozin. Exton said physicians have identified an unmet need in non-obstructive HCM, where he said there are currently no approved treatment options.

He said the company believes sotagliflozin could provide an oral, once-daily treatment option with potential use across both obstructive and non-obstructive disease, depending on study results and regulatory decisions. Exton also cited the drug’s existing heart-failure safety record and said its potential profile could differ from currently approved CMIs, which can require risk-management procedures related to potential reductions in ejection fraction.

Type 1 Diabetes Resubmission Planned In type 1 diabetes, Exton said the third-party STENO1 study has completed the recruitment and drug-exposure requirements Lexicon believes are needed to support a U.S. Food and Drug Administration resubmission for sotagliflozin.

He said STENO1 is an open-label Danish cardiovascular outcomes study and that observed diabetic ketoacidosis, or DKA, rates in the sotagliflozin group have been similar to standard of care and lower than rates observed in Lexicon’s prior inTandem program. The company plans to resubmit its application in the fourth quarter and said a potential FDA decision could occur in 2027.

Partnership and Pipeline Updates Exton also discussed Lexicon’s partnerships with Viatris and Novo Nordisk. Viatris has submitted and received approvals for sotagliflozin in the United Arab Emirates and Bahrain for heart failure, he said, while additional submissions in markets outside the U.S. and European Union are continuing.

For LX9851, Lexicon’s non-incretin obesity mechanism partnered with Novo Nordisk, Exton said Lexicon has received three $10 million milestone payments this year, in addition to $45 million received in the prior year. He said the agreement carries up to $1 billion in potential milestone payments, along with high-single-digit to low-double-digit sales royalties.

Lexicon is also preparing for a potential Phase III program for pilavapadin in diabetic peripheral neuropathic pain and plans to present additional preclinical information later this year regarding AAK1 biology and potential further indications, Exton said.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc is a biopharmaceutical company that discovers and develops medicines for human disease. Founded in 1995 and headquartered in The Woodlands, Texas, the company uses its drug-discovery platform and expertise in biology to identify potential treatments for conditions with significant unmet medical needs.

Lexicon's marketed products include XERMELO (telotristat ethyl), an oral medicine used to treat carcinoid syndrome diarrhea in adults whose symptoms are not adequately controlled by somatostatin analog therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Lexicon Pharmaceuticals Right Now?Before you consider Lexicon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.

While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY:

Citi 2026 Biopharma Back to School Conference
September 9, 2026, 11:20–11:55 AM (Eastern Time)

2026 Cantor Global Healthcare Conference
September 10, 2026, 3:20–3:50 PM (Eastern Time)

H.C. Wainwright 28th Annual Global Investment Conference
September 14, 2026, 9:00–9:30 AM (Eastern Time)

The live events and replays of the presentations can be accessed via the Events page on the company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales

THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders.

LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.

With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851.

“This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement."

The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.

About LX9851
LX9851, discovered by Lexicon and in development by Novo Nordisk, is a potent and selective oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5)​. ACSL5 plays a key role in the metabolic pathway which regulates fat accumulation and energy balance. Preclinical in vivo efficacy data presented at Obesity Week 2024 show that LX9851, when combined with semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone. Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation in the preclinical studies.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement   
This press release contains “forward-looking statements,” including statements relating to the preclinical and clinical development of LX9851, Lexicon’s financial position and long-term outlook on its business, growth and future operating results, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.  

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]

Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.

Total revenue for the quarter ended June 30 was $0.7 million, compared with $28.9 million a year earlier. Second-quarter 2026 revenue represented net sales of INPEFA, while the prior-year quarter included $27.5 million of licensing revenue related to the company’s agreement with Novo Nordisk, in addition to INPEFA sales.

Get LXRX alerts:

Lexicon recorded a net loss of $31.8 million, or $0.07 per share, compared with net income of $3.3 million, or $0.01 per share, in the second quarter of 2025. The 2026 loss included a $4.3 million loss on early debt extinguishment associated with the repayment of term loans from Oxford Finance. Non-cash stock-based compensation expense was $3.3 million, compared with $3.2 million a year earlier.

SONATA-HCM Enrollment Completed Chief Executive Officer Mike Exton said Lexicon completed enrollment in SONATA-HCM, a Phase III study evaluating sotagliflozin in patients with hypertrophic cardiomyopathy, or HCM. The company said the study was significantly over-enrolled and described it as the largest Phase III study to date involving both obstructive and non-obstructive HCM.

Lexicon expects to report top-line results from the trial in the first quarter of 2027. The study’s primary efficacy endpoint is the change from baseline to week 26 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, or KCCQ-CSS, across the overall study population.

Chief Medical Officer Craig Granowitz said the trial enrolled a substantial majority of patients with non-obstructive HCM, a population for which the company said treatment options remain limited, along with a meaningful cohort of obstructive HCM patients. Patients receiving stable guideline-directed HCM therapy, including cardiac myosin inhibitors, were permitted to enroll.

During the question-and-answer session, Granowitz said the trial is powered for the combined obstructive and non-obstructive population. He added that the over-enrollment increased management’s confidence in the study’s ability to assess the primary endpoint and that the company expects sufficient obstructive-HCM enrollment to evaluate results in both groups.

Exton said Lexicon views sotagliflozin as potentially usable either alone or alongside cardiac myosin inhibitors, though any future commercial positioning would depend on clinical and regulatory outcomes.

ZYNQUISTA Resubmission Targeted for Fourth Quarter Lexicon said the STENO-1 study, an open-label investigator-initiated study being conducted by the Steno Diabetes Center in Denmark, is expected to reach the patient-exposure level requested by the U.S. Food and Drug Administration by the end of August.

The FDA had requested a prospective study, adequate patient exposure and diabetic ketoacidosis, or DKA, rates below those seen in Lexicon’s earlier clinical trials to support resubmission of the ZYNQUISTA new drug application. Granowitz said DKA rates among sotagliflozin-treated patients in STENO-1 have been similar to the study’s standard-of-care group and below rates observed in Lexicon’s prior inTandem studies.

The company expects to complete the administrative work needed to collect and transfer patient-level data after the exposure threshold is reached. Lexicon currently anticipates an NDA resubmission during the fourth quarter, with Granowitz citing the end of October as the company’s current estimate.

In response to an analyst question on potential review timing, Exton said a six-month review following an end-of-October filing could place a decision in the second quarter of 2027. He noted, however, that the company intends to discuss whether a quicker review may be possible because the FDA has already received much of the information expected in the filing.

Outside the U.S. and Europe, Lexicon licensee Viatris has secured regulatory approvals for sotagliflozin in the United Arab Emirates and Bahrain. Viatris has also submitted applications in more than a dozen additional markets, including Saudi Arabia, Canada and Australia. Regulatory decisions in Canada and Australia are anticipated this year, according to Lexicon.

Earlier-Stage Programs and Financial Position Lexicon said LX9851, an oral small-molecule inhibitor of ACSL5 being developed for obesity, is in a Phase I study being conducted by Novo Nordisk. Lexicon has received two $10 million milestone payments under its license agreement with Novo Nordisk and said it could receive a third $10 million milestone later this year.

The company also said it is conducting preclinical work to explore additional potential indications for pilavapadin, which uses an AAK1 inhibition mechanism. Lexicon said it expects to share preclinical data as early as later this year.

Research and development expense rose to $17.4 million from $15.7 million a year earlier, driven by higher external costs related to the SONATA-HCM trial. Selling, general and administrative expense increased to $9.8 million from $9.4 million.

As of June 30, Lexicon had $190.6 million in cash equivalents and short-term investments, compared with $125.2 million in cash equivalents, short-term investments and restricted cash at the end of 2025.

In May, the company announced a $100 million debt facility with Hercules Capital. An initial $55 million tranche was funded at closing and used to repay the Oxford Finance facility. Lexicon may access an additional $20 million subject to clinical, regulatory and financial milestones, while a further $25 million tranche would require Hercules’ consent and meet specified timing requirements.

Lexicon reiterated its 2026 operating expense guidance of $100 million to $110 million, including expected research and development spending of $63 million to $68 million and selling, general and administrative spending of $37 million to $42 million. The company said it began targeted pre-commercial investments during the second quarter, including medical education, marketing preparation and market-access activities.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Lexicon Pharmaceuticals Right Now?Before you consider Lexicon Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.

While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Lexicon Pharmaceuticals (LXRX - Free Report) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this drugmaker would post a loss of $0.04 per share when it actually produced break-even earnings, delivering a surprise of +100%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Lexicon, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.69 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 88.73%. This compares to year-ago revenues of $28.87 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Lexicon shares have added about 113% since the beginning of the year versus the S&P 500's gain of 12.8%.

What's Next for Lexicon?While Lexicon has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Lexicon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.06 on $11.16 million in revenues for the coming quarter and -$0.17 on $37.95 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Ovid Therapeutics (OVID - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.

This company is expected to post quarterly loss of $0.10 per share in its upcoming report, which represents a year-over-year change of -66.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Ovid Therapeutics' revenues are expected to be $0.15 million, down 97.6% from the year-ago quarter.

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. 

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]

Key Takeaways Lexicon is advancing sotagliflozin in a phase III HCM study, with top-line data expected in Q1 2027.Lexicon's Novo Nordisk-partnered LX9851 entered phase I in 2026, with milestone-payment potential.LXRX targets a 2026 T1D NDA resubmission for sotagliflozin, pending STENO1 & fulfillment of FDA requirements. Lexicon Pharmaceuticals (LXRX - Free Report) is advancing its cardiometabolic franchise, led by its sole marketed drug, sotagliflozin. Sotagliflozin, an oral inhibitor of sodium-glucose cotransporter types I and II (SGLT1 and SGLT2), has been marketed in the United States as Inpefa since 2023 to reduce the risk of cardiovascular death and heart failure in adults. Lexicon has granted Viatris (VTRS - Free Report) the rights to develop, seek regulatory approvals for and commercialize sotagliflozin in markets outside the United States and Europe.

The company’s top line comprises product revenues from Inpefa, licensing and milestone revenues from LX9851, its obesity-focused asset partnered with Novo Nordisk (NVO - Free Report) and royalties from a previously commercialized product, Xermelo.

In 2020, Lexicon sold its commercial rights to Xermelo under an asset purchase and sale agreement to TerSera Therapeutics, receiving upfront payments while retaining certain ongoing royalty and milestone payment rights on Xermelo from TerSera Therapeutics.

The company is entering a catalyst-rich period, with several potentially transformative milestones expected across its cardiometabolic pipeline over the next 12 months.

Year to date, LXRX shares have surged 74.8% against the industry’s 1.7% decline.

Image Source: Zacks Investment Research

Sotagliflozin Becomes a Multi-Indication Growth Asset for LXRXLexicon is actively pursuing label expansion opportunities for sotagliflozin beyond its current heart failure indication. The company is enrolling patients in the pivotal phase III SONATA-HCM study evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM), a chronic and progressive heart disease characterized by abnormal thickening of the heart muscle. Enrollment is expected to be completed in mid-2026, with top-line data anticipated in the first quarter of 2027. Positive clinical data could substantially increase investor confidence in the long-term growth trajectory of the drug.

Beyond HCM, LXRX is also pursuing approval of sotagliflozin for glycemic control in adults with type I diabetes (T1D) and remains on track for potential new drug application (NDA) resubmission and regulatory approval in 2026, subject to the successful completion of the ongoing STENO1 study and fulfillment of FDA data requirements. If approved, the company will market the drug under the brand name Zynquista.

To remind investors, Lexicon received a complete response letter from the FDA in 2019, which expressed concerns regarding the risk of diabetic ketoacidosis, a potentially serious complication associated with SGLT inhibitor use in patients with T1D. The agency requested additional data to better characterize the drug's safety profile and demonstrate that the benefits outweigh the risks.

NVO-LXRX Licensing Agreement to Boost Cash PositionLexicon entered into a licensing agreement withNovo Nordisk in 2025,under which the latter is developing LXRX’s LX9851, a first-in-class oral small-molecule inhibitor of acyl-CoA synthetase 5 for obesity and associated metabolic disorders. NVO initiated a phase I study in March 2026, which is expected to be completed in the first quarter of 2027. Per the licensing agreement, Lexicon has already received $55 million in upfront and milestone payments and remains eligible for up to $1 billion in additional development, regulatory and commercial milestones, along with tiered royalties on future sales.

Lexicon’s Another Pipeline Asset on the MoveAnother pipeline asset of Lexicon is pilavapadin (LX9211), an investigational oral, non-opioid therapy for diabetic peripheral neuropathic pain (DPNP). Following FDA clearance, the company plans to advance the candidate into phase III development. The primary endpoint will be the change in average daily pain score. If approved, pilavapadin would be the first oral, non-opioid therapy approved for neuropathic pain in more than 20 years. Lexicon is exploring strategic partnership opportunities to support the therapy's global development and commercialization.

Lexicon highlighted encouraging preclinical findings in March, suggesting that pilavapadin may have potential as a novel oral treatment for spasticity associated with conditions such as multiple sclerosis and spinal cord injury.

LXRX's Zacks Rank & EstimatesLexicon currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Over the past 30 days, estimates for LXRX’s loss per share have remained unchanged at 17 cents for 2026 and 24 cents for 2027.

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.

Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.